We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

128 hedge funds and large institutions have $371M invested in AbCellera Biologics in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more call options, than puts

Call options by funds: $3.46M | Put options by funds: $1.81M

32% more capital invested

Capital invested by funds: $280M → $371M (+$90.5M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

1% less funds holding

Funds holding: 129 → 128 (-1)

6.01% less ownership

Funds ownership: 42.08% → 36.07% (-6%)

16% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 44

Holders
128
Holders Change
-1
Holders Change %
-0.78%
% of All Funds
1.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
37
Reduced
44
Closed
18
Calls
$3.46M
Puts
$1.81M
Net Calls
+$1.65M
Net Calls Change
+$1.89M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.29M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$3.55M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.68M
4
Two Sigma Investments
Two Sigma Investments
New York
+$2.45M
5
DCM
Driehaus Capital Management
Illinois
+$1.24M

Top Sellers

Rank Fund Capital Flow
1
VOYA Investment Management
VOYA Investment Management
Georgia
-$23.7M
2
UBS AM
UBS AM
Illinois
-$17.9M
3
PM
Prosight Management
Texas
-$6.28M
4
UBS Group
UBS Group
Switzerland
-$4.07M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$94.4M – – –
Capital World Investors
2
Capital World Investors
California
$45.8M – – –
Baillie Gifford & Co
3
Baillie Gifford & Co
United Kingdom
$35.5M -$2.08M -835,828 -7%
UBS AM
4
UBS AM
Illinois
$29.1M -$17.9M -7,199,444 -46%
Two Sigma Investments
5
Two Sigma Investments
New York
$14.1M +$2.45M +984,063 +31%
ACH
6
ArrowMark Colorado Holdings
Colorado
$14.1M – – –
Two Sigma Advisers
7
Two Sigma Advisers
New York
$14M +$3.55M +1,425,500 +54%
BlackRock
8
BlackRock
New York
$12.6M +$260K +104,586 +3%
UBS Group
9
UBS Group
Switzerland
$11.8M -$4.07M -1,634,258 -32%
Millennium Management
10
Millennium Management
New York
$11.7M +$6.29M +2,527,880 +291%
O
11
OrbiMed
New York
$11.5M -$2.08M -836,200 -20%
Renaissance Technologies
12
Renaissance Technologies
New York
$11.3M +$1.03M +413,400 +14%
Citadel Advisors
13
Citadel Advisors
Florida
$9.91M +$2.68M +1,075,286 +59%
TCM
14
Tang Capital Management
California
$8.92M – – –
GP
15
Guardian Partners
Canada
$7.54M – – –
Morgan Stanley
16
Morgan Stanley
New York
$3.42M -$732K -294,089 -23%
NHAS
17
Novo Holdings A/S
Denmark
$2.24M -$1.18M -474,386 -42%
Norges Bank
18
Norges Bank
Norway
$2.16M – – –
State Street
19
State Street
Massachusetts
$2.11M -$32K -12,848 -2%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$2.04M +$860K +345,643 +139%
IP
21
Intellectus Partners
California
$1.88M – – –
Lazard Asset Management
22
Lazard Asset Management
New York
$1.75M -$805K -323,368 -39%
DCM
23
Driehaus Capital Management
Illinois
$1.71M +$1.24M +499,922 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$1.39M +$42K +16,885 +4%
HF
25
HRT Financial
New York
$1.27M +$442K +177,730 +92%
1
2 3 4 5

ABCL Hedge Fund Activity: Q2 2025 in Review

128 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2025, worth a combined $371M — up 32% from $280M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ABCL positions and 18 closed out — a net gain of 1 holder — while 37 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.29M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $23.7M sold.

  • 128 institutional investors held AbCellera Biologics (ABCL) as of Q2 2025, down from 129 in Q1 2025.
  • Funds reported $371M of AbCellera Biologics stock for Q2 2025, up 32% quarter-over-quarter.
  • 19 funds opened new AbCellera Biologics positions in Q2 2025 and 18 closed out, a net change of +1 holder.
  • The largest AbCellera Biologics buyer in Q2 2025 was Millennium Management, an estimated $6.29M added.
  • The largest AbCellera Biologics seller in Q2 2025 was VOYA Investment Management, an estimated $23.7M sold.

Based on aggregated 13F filings for Q2 2025.